Welcome to our dedicated page for Xenetic Biosciences SEC filings (Ticker: XBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xenetic Biosciences filings document the regulatory record for a Nasdaq-listed biopharmaceutical company developing DNase-based immuno-oncology technologies. Its Form 8-K reports cover operating and financial results, material events, capital-structure disclosures, equity incentive activity and governance matters tied to the company’s common stock.
Proxy materials describe annual meeting proposals, director elections, shareholder voting mechanics and board-related governance. The filing record also captures disclosures related to the company’s DNase program, collaboration activity, compensation arrangements, quorum and proxy-solicitation matters, and other formal updates affecting corporate reporting and stockholder approvals.
Xenetic Biosciences, Inc. reported that it issued a press release with its financial results for the three months ended June 30, 2025. The company furnished this press release as an exhibit to a current report, making the quarter’s performance details available to investors through that document.
The disclosure also includes an extensive caution about forward-looking statements, noting that expectations are subject to numerous risks and uncertainties described in Xenetic’s other SEC reports. The company’s common stock continues to trade on The Nasdaq Stock Market under the symbol XBIO.
Xenetic Biosciences reported a narrowing net loss driven by lower operating expenses while continuing to receive royalties from Takeda. Royalty revenue was $589,897 for the quarter and $1,183,158 for the six months ended June 30, 2025. The company recorded a net loss of $688,703 for the quarter and $1,591,844 for the six-month period. Cash totaled $4,779,846 at June 30, 2025 and working capital was approximately $4.5 million, while total assets were $5.35 million.
Operating costs fell year-over-year as R&D and general and administrative expenses declined, largely reflecting lower personnel and severance-related items recognized in 2024. Management states existing resources are adequate to fund operations for at least twelve months from issuance of these financial statements, but the company anticipates the need for additional capital longer term to advance its DNase clinical program and other initiatives.